Aimovig ® (erenumab) godkänt för behandling av migrän hos vuxna

Aimovig godkänt för behandling av migrän hos vuxna

Novartis announced today that the European Commission (EC) approved Aimovig ® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days per month. Aimovig is the first and only treatment specifically designed

for migraine prevention to be approved in the Eur opean Union, Switzerland, the US and Australia. It works by blocking a receptor called the calcitonin gene-related peptide receptor(CGRP-R) which plays a critical role in mediating the incapacitating pain of migraine. In the extensive clinical program of 2,600 patients, those on Aimovig experienced significant reductions in their number of migraine days per month, with a safety and tolerability profile similar to placebo1-3.

Aimovig can be self-administered or administered by another trainedperson every four weeks with the SureClick® autoinjectorpen, an established devicecommonly used for a range of different conditions.“Migraine matters. It is a painful, highly disruptive neurological disease that affects all aspects of life, from going to work to spending time with family and friends,” said Patrick Little, President of the European Migraine and Headache Alliance. “A treatment specifically designed for migraine prevention is a much – welcomed innovation and could transform lives of patients for whom current therapies do not work or are not well tolerated.” Aimovig showed efficacy even in a difficult -to-treat population. It is the only CGRP -R pathway

therapy specifically studied in patients who had failed on two to four previous treatmentscommonly used for migraine prevention6.

Fullständig release här.